Bassam Sonbol: Randomized Phase II Trial of Pazopanib vs Placebo in Extrapancreatic NETs
Bassam Sonbol, Oncologist at Mayo Clinic Arizona, shared a post on X:
“Alliance A021202 (Bergsland et al, JCO). Randomized phase II of pazopanib vs placebo in extrapancreatic NETs (epNET).
PFS improved (11.8 vs 7.6 mo, HR 0.54).
No OS benefit. More toxicity plus on-study deaths.”
Title: Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)
Authors: Emily K. Bergsland, Susan Geyer, Timothy R. Asmis, Spencer C. Behr, J. Philip Kuebler, Priya Kumthekar, Gina Mazza, Michael L. Maitland, Donna Niedzwiecki, Andrew B. Nixon, Lawrence Howard Schwartz, Jonathan R. Strosberg, Alan P. Venook, Eileen M. O’Reilly, Jeffrey A. Meyerhardt
Read The Full Article at JCO Oncology.
More Posts Featuring NETs.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023